Current Investors

Promethera® is committed to develop life-changing new cell therapies for patients suffering from serious liver diseases.

As an innovator in the emerging field of cell-based medicines, Promethera® is driven by the ambition of creating a diverse portfolio of drug candidates with partners and on our own account. This vision has attracted a broad range of European and Asian institutional and corporate investors throughout the Company’s development steps as a privately-held organization.

* Essentially HNWI and private investors

Promethera® has garnered the support of important investors that operate globally and spread accross three continents – Europe, North America and Asia.

Since inception, Promethera® has raised EUR 120 million in equity and semi-equity, not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.